Creating a new type of CAR-T therapy for pancreatic cancer
Development of a Novel Armored CAR-T Immunotherapeutic for Pancreatic Cancer
This study is testing a new type of CAR-T therapy that aims to help fight pancreatic cancer by training special immune cells to better target and destroy the cancer cells, and it’s looking for patients to join the trials to see how well it works and if it’s safe.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cambium Oncology LLC NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11069693 on NIH RePORTER |
What this research studies
This research focuses on developing a novel CAR-T immunotherapy specifically designed to combat pancreatic cancer, which is known for its challenging treatment landscape. The approach involves engineering CAR T cells to target a specific marker found in pancreatic tumors and to secrete a receptor antagonist that counteracts the immunosuppressive environment created by the tumor. By enhancing the effectiveness of these CAR T cells, the research aims to improve their ability to attack and eliminate cancer cells. Patients may be involved in trials to assess the safety and efficacy of this innovative treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who have not responded well to existing therapies.
Not a fit: Patients with other types of cancer or those who are not diagnosed with pancreatic cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment outcomes for patients with pancreatic cancer by enhancing the effectiveness of CAR T cell therapy.
How similar studies have performed: While CAR T cell therapies have shown success in treating hematologic malignancies, this specific approach for pancreatic cancer is novel and has not been extensively tested.
Where this research is happening
Atlanta, United States
- Cambium Oncology LLC — Atlanta, United States (Active)
Researchers
- Principal investigator: Altman, Gary G. — Cambium Oncology LLC
- Study coordinator: Altman, Gary G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.